Skip to content

YPOG advises Wallaby Medical on acquisition of neurovascular leader phenox

Dr. Tim<br>Schlösser Dr. Tim
Schlösser
Dr. Malte<br>Bergmann Dr. Malte
Bergmann
Dr. Stephan<br>Bank Dr. Stephan
Bank
Dr. Jörn<br>Wöbke Dr. Jörn
Wöbke
Dr. Johannes<br>Janning Dr. Johannes
Janning
Dr. Benedikt<br>Flöter Dr. Benedikt
Flöter
Matthias <br>Kresser Matthias
Kresser
Ann-Kristin <br>Lochmann Ann-Kristin
Lochmann
Barbara<br>Hasse Barbara
Hasse
Christiane<br>Schnitzler Christiane
Schnitzler

Berlin – A YPOG team led by Tim Schlösser comprehensively advised global medical technology company Wallaby Medical on the acquisition of German-based neurovascular market leader phenox GmbH as well as its sister company femtos GmbH. The transaction was completed for a consideration of approximately €500 million, including milestone payments. Wallaby Medical funded the acquisition of phenox from the proceeds of its Series D financing round supported by leading healthcare investors.

Since 2019, Wallaby Medical and phenox have been strategic partners. phenox exclusively distributes Wallaby's Avenir® Coil System in the US and Europe, as well as Wallaby's Esperance™ aspiration catheters in the US market. Now completed, the acquisition marks one of the largest cross-border transactions in the medical technology industry and is driven by strong growth opportunities in terms of product portfolio as well as geographic coverage. Prospectively, the company will become a global leader, providing a wide range of neurovascular technologies and solutions for customers and patients around the world, covering the US, China, Europe, Japan and other international markets.

After the successful closing, Michael Alper, CEO of Wallaby, will now become CEO of the combined organization. Prof. Dr.-Ing. Hermann Monstadt, founder of phenox, will take over the role of Managing Director of phenox. All existing phenox product brands will be maintained.

 

Advisors Wallaby Medical:

Dr. Tim Schlösser (Lead, Corporate/Transactions), Partner
Dr. Malte Bergmann (Tax/Transactions), Partner
Dr. Stephan Bank (Corporate/Transactions), Partner
Dr. Jörn Wöbke (Corporate/Transactions), Partner
Dr. Johannes Janning (Corporate/Transactions), Associated Partner
Dr. Benedikt Flöter (IP/IT), Associated Partner
Matthias Kresser (Corporate/Transactions), Associated Partner
Ann-Kristin Lochmann (Tax/Transactions), Associated Partner
Barbara Hasse (Corporate/Transactions), Associate
Christiane Schnitzler (Transactions), Associate

About Wallaby Medical

Wallaby Medical is a global innovative medical technology company focused on developing and commercializing neurovascular interventional products for treating stroke. Wallaby 's product portfolio includes the Avenir® Coil System, a technically differentiated neuro embolic coil system for treating intracranial aneurysms and other neurovascular abnormalities, the Esperance™ Aspiration Catheter, cleared in the U.S. and China for ischemic stroke treatment procedures, and the Esperance™ Distal Access Catheter, which was approved for delivery assistance in China. In addition, Wallaby has a full range of neurovascular products under development. Wallaby 's products are currently marketed in over 30 countries and regions. For more information, visit www.wallabymedical.com. 

About phenox

Since its foundation in 2005, phenox has developed into a global innovation leader in neurovascular devices for the interventional treatment of strokes. The company has a broad product portfolio covering both ischemic and haemorrhagic stroke as well as Access & Support. The key product lines of phenox include the p64/p48 range of flow diverters for the treatment of intracranial aneurysms and the pRESET range of stent retrievers for the mechanical thrombectomy of ischemic strokes. Additionally, phenox has proprietary coating technologies for the enhancement of its permanent and short-term implants. The products of phenox are marketed in over 45 countries worldwide based on internationally leading clinical data. phenox has subsidiaries in Italy, the UK, Ireland and the U.S. For further information please visit https://phenox.net/international/ . 

 

Download Press Release

 

 

About us

YPOG is a law firm specialized on tax and business law which is active in the core fields of Tax, Funds and Transactions. The team at YPOG represents a broad client base, which ranges from emerging technology companies and family-run SMEs to large corporations as well as private equity and venture capital funds. YPOG is one of the leading advisors for venture capital, private equity and fund structuring in Germany. The firm and its partners have been recognized nationally and internationally by JUVE, Best Lawyers, Legal 500, Focus and Chambers and Partners. Today, YPOG has more than 100 experienced lawyers and tax specialists and a notary, in three offices in Berlin, Hamburg and Cologne.